HOW MUCH OF ANTI-CGRP MONOCLONAL ANTIBODY PREVENTIVE THERAPY FOR MIGRAINE IS CONTEXTUAL (PLACEBO) EFFECT?

被引：0
|
作者：
Forbes, Raeburn B. [1 ]
McCarron, Mark O. [2 ]
机构：
[1] Southern HSC Trust, Portadown, North Ireland
[2] Western HSC Trust, Londonderry, North Ireland
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2019年 / 90卷 / 12期
关键词：
D O I：
10.1136/jnnp-2019-ABN-2.18
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
14.57
引用
下载
收藏
页码：E13 / E13
页数：1
相关论文
共 50 条
  • [41] Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
    Sevivas, Hugo
    Fresco, Paula
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [42] Could symptom severity predict the response to anti-CGRP monoclonal antibodies in migraine?
    Membrilla, J.
    Ruiz Castrillo, M.
    Sastre Real, M.
    Sanchez Casado, L.
    Trillo Marino, E.
    Corral, C.
    Estebas, C.
    Gonzalez Sarmiento, R.
    Lorenzo, M.
    Diaz de Teran, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 413 - 413
  • [43] Randomized, Double-blind, Placebo-controlled Trial of ALD403 (eptinezumab), an Anti-CGRP Monoclonal Antibody for the Prevention of Chronic Migraine
    Smith, J.
    Dodick, D. W.
    Goadsby, P. J.
    Silberstein, S. D.
    Lipton, R. B.
    Hirman, J.
    HEADACHE, 2017, 57 : 130 - 130
  • [44] Do anti-CGRP drugs have a role in migraine aura therapy?
    Matteo, Eleonora
    Pensato, Umberto
    Favoni, Valentina
    Giannini, Giulia
    Pierangeli, Giulia
    Cevoli, Sabina
    JOURNAL OF NEUROLOGY, 2021, 268 (06) : 2273 - 2274
  • [45] Do anti-CGRP drugs have a role in migraine aura therapy?
    Eleonora Matteo
    Umberto Pensato
    Valentina Favoni
    Giulia Giannini
    Giulia Pierangeli
    Sabina Cevoli
    Journal of Neurology, 2021, 268 : 2273 - 2274
  • [46] Impact of preventive anti-CGRP therapies on Insomnia Severity Index scale in patients with migraine
    Gonzalez-Martinez, A.
    Lazaro, I. Fernandez
    Alcaide, N. Lopez
    Quintas, S.
    Vivancos, J.
    Gago-Veiga, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 483 - 483
  • [47] Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one
    Fresan-Restituto, Daniel
    Lacalle-Fabo, Esther
    Martin-Bujanda, Maria
    Teresa Sarobe-Carricas, M.
    REVISTA DE NEUROLOGIA, 2023, 76 (06) : 213 - 216
  • [48] Work impact and cost-effectiveness of anti-CGRP monoclonal antibodies in patients with migraine
    Lazaro, C.
    Caronna, E.
    Alpuente, A.
    De la Torre, A.
    Torres, M.
    Pozo-Roisch, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 487 - 488
  • [49] DO MULTIPLE TREATMENT CYCLES WITH ANTI-CGRP MONOCLONAL ANTIBODIES MODIFY MIGRAINE COURSE?
    Aurilia, C.
    Egeo, G.
    Proietti, S.
    Torelli, P.
    Cevoli, S.
    D'Onofrio, F.
    Bonassi, S.
    Barbanti, P.
    HEADACHE, 2023, 63 : 126 - 126
  • [50] Anti-CGRP Monoclonal Antibodies for the Treatment of Migraine with Aura: a prospective observational cohort study
    Braca, S.
    Russo, C.
    Miele, A.
    Stornaiuolo, A.
    Sansone, M.
    De Simone, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 376 - 376
12345